首页> 美国卫生研究院文献>Annals of Translational Medicine >An editorial on the TAILOR trial—further support for the addition of cetuximab to FOLFOX-4 in the treatment of RAS wild-type metastatic colorectal cancer

【2h】

An editorial on the TAILOR trial—further support for the addition of cetuximab to FOLFOX-4 in the treatment of RAS wild-type metastatic colorectal cancer

机译：TAILOR试验的社论-进一步支持将西妥昔单抗添加至FOLFOX-4中以治疗RAS野生型转移性结直肠癌

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Annals of Translational Medicine
作者
Joanna Blanco; Michael Karass;
展开▼
作者单位

展开▼
年(卷),期 2018(6),Suppl 2
年度 2018
页码 S114
总页数 3
原文格式 PDF
正文语种
中图分类
关键词
入库时间 2022-08-17 16:08:41

相似文献

外文文献
中文文献
专利

1. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial [J] . Qin Shukui, Li Jin, Wang Liwei, Journal of Clinical Oncology . 2018,第30期

机译：一线Cetuximab和Leucovorin，氟尿嘧啶和Oxaliplatin（Folfox-4）对RAS野生型转移性结肠直肠癌患者的疗效和耐受性，与Folfox-4相比：开放标签，随机，第III期裁缝试验
2. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study) [J] . Julen Fernandez-Plana, Carlos Pericay, Guillermo Quintero, BMC Cancer . 2014,第1期

机译：双周西妥昔单抗联合FOLFOX-4一线治疗野生型KRAS转移性结直肠癌：II期开放标签临床试验的最终结果（OPTIMIX-ACROSS研究）
3. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：用伊立替康/西替昔单抗的治疗序列，然后进行Folfox-4或转移性结肠直肠癌患者的反向策略，在第一线Folfiri / Bevacizumab后进展：用于研究胃肠癌期III的意大利组，随机试验比较两种治疗序列结肠直肠转移性患者
4. PIK3CA Pathway and CTNNB1 Determine Poor Response of Cetuximab in Right-Sided Metastatic Colorectal Cancer [C] . Pi-Yueh Chang International Molecular Medicine Tri-Conference. . 2019

机译：Pik3CA途径和CTNNB1确定右侧转移性结肠直肠癌中西妥昔单抗的良差
5. Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth [D] . Wu Zhiwen, 吴智闻 2019

机译：西妥昔单抗和溶瘤病毒Canerpaturev的组合协同抑制人类大肠癌的生长。
6. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin Fluorouracil and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label Randomized Phase III TAILOR Trial [O] . Shukui Qin, Jin Li, Liwei Wang, -1

机译：一线西妥昔单抗联合白细胞素氟尿嘧啶和奥沙利铂（FOLFOX-4）与FOLFOX-4在RAS野生型转移性结直肠癌患者中的疗效和耐受性：开放标签随机III期TAILOR试验
7. An editorial on the TAILOR trial—further support for the addition of cetuximab to FOLFOX-4 in the treatment of RAS wild-type metastatic colorectal cancer [O] . Joanna Blanco, Michael Karass 2018

机译：裁缝试验中的一个社论 - 进一步支持加入西妥昔单抗至Folfox-4治疗Ras野生型转移性结肠直肠癌

An editorial on the TAILOR trial—further support for the addition of cetuximab to FOLFOX-4 in the treatment of RAS wild-type metastatic colorectal cancer

著录项

相似文献

相关主题

期刊订阅